-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
April 2021
-
NCI Launches the Cancer Moonshot SM Biobank to Accelerate Research in Cancer Treatment
The U.S. National Cancer Institute (NCI) Cancer Moonshot Biobank launched in September 2020, with the aim of accelerating cancer research by creating a resource of well-annotated, longitudinal cancer biospecimens from patients receiving standard-of-care therapy. The Biobank will serve research needs of funded grantees working to better understand the mechanisms and systems biology of drug resistance…
-
Consortium of Advocacy Groups, Professional Societies, and Industry Develops Consistent Language for Cancer Precision Medicine Testing
In recent years, precision medicine has begun to play an increasingly important role in cancer care. Advanced diagnostic testing, including testing for somatic mutations, non-genomic biomarkers, and germline mutations, is likely to be involved to some degree in comprehensive treatment for most cancers. Despite the relevance of this type of testing as a major component…
-
Immunotherapy Use in Patients With Lung Cancer and Comorbidities
Because nearly one-half of patients with advanced cancer are eligible for immune checkpoint inhibitor (ICI)–based treatment, these therapies are now in widespread clinical use.1 ICIs—whether as monotherapy, in checkpoint inhibitor combinations, with chemotherapy, or after concurrent chemoradiation—are now incorporated into treatment regimens for most types of lung cancer, resulting in prolonged responses for a small…
-
ASCO and Ontario Health Publish Joint Guideline Update on Systemic Therapy for Stage IV NSCLC
In February 2021, the American Society of Clinical Oncology (ASCO) and Ontario Health (Cancer Care Ontario) published a joint guideline update to the 2017 ASCO guidelines regarding systemic therapy for stage IV NSCLC. This update focused on therapy for patients with stage IV NSCLC with driver alterations, and it discussed treatment options for ROS1 fusions…
-
Voice from Asia: Combination of Immune Checkpoint Inhibitors With Chemotherapy for Advanced Non-squamous NSCLC
The immune checkpoint inhibitors (ICIs) monotherapy has resulted in significant improvements in PFS and OS in advanced NSCLC when compared with chemotherapy alone, and it has become the standard of care as first-line treatment for patients with EGFR- and ALK-negative advanced NSCLC1 ,2 . However, patients with high PD-L1 expression are preferred population and almost…
-
Deeper Dive Toxicity of Lung SBRT and Concurrent Immunotherapy Combinations: What We Know and What We Still Need to Learn
In Reference To: Tian S, Switchenko JM, Buchwald ZS, et al. Lung Stereotactic Body Radiation Therapy and Concurrent Immunotherapy: A Multicenter Safety and Toxicity Analysis. Int J Radiat Oncol Biol Phys. 2020;108(1):304-313.
-
The IASLC Mourns the Loss of Dr. Pierre Massion
“Pierre was not only an amazing physician and scientist, but he was also a truly amazing, kind, generous, and loving soul who always had a smile on his face and a kind word for everyone he met.”